1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Getting A Good Start: Sanofi Extends Dupixent's Potential To Younger Patients

 
• By John Davis

Sanofi/Regeneron’s pioneering biologic, dupilumab, is growing its potential market before the advent of competing molecules. An EU approval extension, allowing use in adolescents as well as in adults, and positive Phase III results in children aged six to 11 years with severe atopic dermatitis, should help.

Scratching
Itching is a distressing symptom of atopic dermatitis • Source: Shutterstock

Gaining EU approval for the use of the biologic atopic dermatitis therapy Dupixent (dupilumab) in adolescents with moderate-to-severe atopic dermatitis, and positive top-line results in children aged six to 11 years with severe atopic dermatitis, will likely cement the lead currently enjoyed by Sanofi and its collaborator, Regeneron Pharmaceuticals Inc., in developing and marketing a biologic for the condition.

However, there are a plethora of biologics in early and late-stage clinical development for atopic dermatitis, indicating the therapeutic segment is likely to become highly competitive in the not-to-distant future – a recent Market Spotlight Report on Atopic Dermatitis from Datamonitor Healthcare, published on 25 July, says late-clinical stage investigational products for the condition include Pfizer Inc.’s abrocitinib, Eli Lilly & Co.’s Olumiant (baricitinib), AbbVie Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Almirall Looks To Dominate Across Derma Spectrum

 
• By Kevin Grogan

CEO Carlos Gallardo tells Scrip the Barcelona-based group has laid the foundations to advance four promising assets that have considerable potential for a variety of dermatological diseases.

Incyte’s Povorcitinib Looks Approvable In HS, But How Competitive?

 
• By Joseph Haas

Incyte’s JAK1 inhibitor meets the primary endpoint in two Phase III hidradenitis suppurativa trials, but the drug may not be able to supplant established biologic therapies.

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.